Hub : Traits :

Number of self-reported non-cancer illnesses

63 significantly associated models · 24 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	11626858	12156236	1	1	6.8e-08	3.8e-07	7.1e-01	100	CLCN6
2	1	71163715	73435171	1	1	1.1e-07	1.3e-09	5.0e-04	67	NEGR1
3	1	220314945	221696457	1	1	1.9e-07	1.3e-06	6.4e-01	99	RP11-295M18.6
4	2	27467598	27949052	1	1	3.7e-08	4.5e-08	1.0e+00	100	FNDC4
5	2	102118712	103555146	1	1	2.6e-07	1.4e-07	1.2e-03	62	IL1RL2
6	5	131008194	132425049	1	1	4.8e-08	1.9e-08	7.6e-04	64	SLC22A5
7	7	1580921	2977732	1	1	1.5e-09	2.6e-13	2.4e-06	58	FTSJ2
8	7	73425238	74494207	2	1	3.4e-09	1.0e-06	4.8e-01	98	STAG3L2
9	12	111154626	113517494	3	1	4.6e-10	6.8e-12	2.3e-04	71	SH2B3
10	15	66797492	68789191	3	1	2.0e-09	7.1e-11	5.9e-04	72	IQCH
11	17	37386899	38783469	2	1	8.1e-08	1.6e-06	7.0e-01	99	GSDMB
12	17	46888301	48347817	2	2	2.5e-09	2.0e-10	1.6e-02	86	RP5-1029K10.2 ZNF652
13	20	57525478	58079512	1	1	3.2e-10	5.7e-11	2.2e-03	78	ZNF831
14	20	61576647	62912463	1	1	3.0e-07	1.2e-06	1.3e-06	1	STMN3

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Triglycerides	26.97	2	1	2.2	0.00	1.0e+00	FNDC4 ZNF652
Blood Eosinophil Count	23.99	9	6	13.3	0.78	1.2e-02	CLCN6 GSDMB IL1RL2 IQCH RP5-1029K10.2 SH2B3 SLC22A5 ZNF652 ZNF831
Respiratory disease	18.82	8	6	13.3	0.90	2.6e-03	GSDMB IL1RL2 IQCH NEGR1 RP5-1029K10.2 SLC22A5 STMN3 ZNF652
Asthma	18.66	6	5	11.1	0.92	8.3e-03	GSDMB IL1RL2 IQCH RP5-1029K10.2 SLC22A5 ZNF652
Asthma (self-reported)	18.58	6	5	11.1	0.92	8.7e-03	GSDMB IL1RL2 IQCH RP5-1029K10.2 SLC22A5 ZNF652
Blood White Count	17.44	7	6	13.3	0.82	2.4e-02	FNDC4 GSDMB RP5-1029K10.2 SH2B3 SLC22A5 STMN3 ZNF652
Allergy	15.19	8	6	13.3	-0.93	9.9e-04	GSDMB IL1RL2 IQCH NEGR1 RP5-1029K10.2 SLC22A5 STMN3 ZNF652
Cardiovascular Disease	12.95	12	7	15.6	0.94	3.7e-06	CLCN6 FNDC4 FTSJ2 IQCH NEGR1 RP11-295M18.6 RP5-1029K10.2 SH2B3 STAG3L2 STMN3 ZNF652 ZNF831
Vascular/heart problems diagnosed by doctor	12.00	10	5	11.1	-0.96	7.6e-06	CLCN6 FTSJ2 IQCH NEGR1 RP11-295M18.6 RP5-1029K10.2 SH2B3 STAG3L2 ZNF652 ZNF831
Systolic Blood Pressure	11.94	8	5	11.1	0.83	1.1e-02	CLCN6 FNDC4 RP5-1029K10.2 SH2B3 STAG3L2 STMN3 ZNF652 ZNF831
Diastolic blood pressure, automated reading	10.93	8	6	13.3	0.91	1.7e-03	CLCN6 IQCH RP5-1029K10.2 SH2B3 STAG3L2 STMN3 ZNF652 ZNF831
High blood pressure	10.84	8	5	11.1	0.96	1.4e-04	CLCN6 IQCH NEGR1 RP5-1029K10.2 SH2B3 STAG3L2 ZNF652 ZNF831
Hypertension (Self-reported)	10.31	8	5	11.1	0.96	1.8e-04	CLCN6 IQCH NEGR1 RP5-1029K10.2 SH2B3 STAG3L2 ZNF652 ZNF831
Allergy or Eczema	10.30	11	4	8.9	0.81	2.7e-03	CLCN6 FNDC4 GSDMB IL1RL2 IQCH NEGR1 RP5-1029K10.2 SH2B3 SLC22A5 STMN3 ZNF652
Taking other prescription medications	10.30	10	2	4.4	0.99	1.1e-07	FTSJ2 GSDMB IL1RL2 IQCH NEGR1 RP11-295M18.6 RP5-1029K10.2 SH2B3 STAG3L2 ZNF652
Hayfever, allergic rhinitis or eczema	10.05	8	4	8.9	0.92	1.1e-03	FNDC4 GSDMB IL1RL2 NEGR1 RP5-1029K10.2 SLC22A5 STMN3 ZNF652
Number of treatments/medications taken	9.91	11	4	8.9	0.99	2.1e-09	FNDC4 FTSJ2 IL1RL2 NEGR1 RP11-295M18.6 RP5-1029K10.2 SH2B3 SLC22A5 STAG3L2 ZNF652 ZNF831
Medication: Ventolin 100micrograms inhaler	9.27	5	2	4.4	0.97	7.4e-03	GSDMB IL1RL2 IQCH SLC22A5 ZNF652
Gout (self-reported)	9.03	3	1	2.2	0.00	1.0e+00	FNDC4 IL1RL2 SH2B3
Systolic blood pressure, automated reading	8.88	6	3	6.7	0.89	1.8e-02	CLCN6 RP5-1029K10.2 SH2B3 STAG3L2 STMN3 ZNF831
High cholesterol (Self-reported)	8.88	2	1	2.2	0.00	1.0e+00	CLCN6 FNDC4
Medication: Blood pressure	8.65	6	4	8.9	0.97	1.1e-03	CLCN6 RP5-1029K10.2 SH2B3 STAG3L2 ZNF652 ZNF831
Hypothyroidism (self reported)	8.48	1	1	2.2	0.00	1.0e+00	SH2B3
Medication for cholesterol, blood pressure or diabetes	8.25	7	3	6.7	-0.98	1.7e-04	CLCN6 FNDC4 NEGR1 SH2B3 STAG3L2 ZNF652 ZNF831
Medication: Blood pressure	7.94	5	3	6.7	0.95	1.4e-02	CLCN6 SH2B3 STAG3L2 ZNF652 ZNF831
Medication: Allopurinol	7.71	2	1	2.2	0.00	1.0e+00	FNDC4 SH2B3
Alcohol intake frequency.	7.62	5	2	4.4	0.93	2.2e-02	FNDC4 FTSJ2 GSDMB NEGR1 STAG3L2
Irritable Bowel Disease (IBD)	7.35	5	3	6.7	0.07	9.1e-01	FNDC4 GSDMB SH2B3 STAG3L2 STMN3
Wheeze or whistling in the chest in last year	7.28	7	2	4.4	0.96	6.6e-04	GSDMB IL1RL2 IQCH RP5-1029K10.2 SLC22A5 STMN3 ZNF652
Hypothyroidism/myxoedema (self-reported)	6.99	1	1	2.2	0.00	1.0e+00	SH2B3
Medication: Levothyroxine sodium	6.90	1	1	2.2	0.00	1.0e+00	SH2B3
Medication for cholesterol	6.35	5	2	4.4	-0.98	2.2e-03	CLCN6 FNDC4 SH2B3 STAG3L2 ZNF831
Long-standing illness, disability or infirmity	6.31	5	0	0.0	1.00	5.9e-05	IQCH NEGR1 RP5-1029K10.2 STAG3L2 ZNF652
Medication: Cholesterol lowering	6.27	3	1	2.2	0.00	1.0e+00	CLCN6 FNDC4 ZNF831
Crohns Disease (2017)	6.18	4	3	6.7	-0.33	6.7e-01	FNDC4 GSDMB STAG3L2 STMN3
Blood Platelet Count	5.90	6	5	11.1	0.72	1.0e-01	CLCN6 FNDC4 GSDMB RP5-1029K10.2 SH2B3 STMN3
Fasting Glucose	5.89	1	1	2.2	0.00	1.0e+00	FNDC4
Medication: Simvastatin	5.44	4	1	2.2	0.97	3.3e-02	CLCN6 FNDC4 FTSJ2 ZNF831
Birth weight of first child	5.27	2	2	4.4	0.00	1.0e+00	CLCN6 SH2B3
Hayfever/allergic rhinitis (self-reported)	5.20	3	2	4.4	0.00	1.0e+00	GSDMB IL1RL2 RP11-295M18.6
Cholesterol lowering medication	5.14	1	1	2.2	0.00	1.0e+00	FNDC4
Comparative body size at age 10	5.08	4	2	4.4	0.92	7.7e-02	FNDC4 IQCH NEGR1 ZNF652
Medication: Seretide 50 evohaler	5.04	3	0	0.0	0.00	1.0e+00	GSDMB SLC22A5 ZNF652
Heart attack/myocardial infarction (self-reported)	5.02	4	0	0.0	0.99	1.0e-02	RP5-1029K10.2 SH2B3 ZNF652 ZNF831
Heart attack	4.92	4	0	0.0	0.99	6.7e-03	RP5-1029K10.2 SH2B3 ZNF652 ZNF831
Ulcerative Colitis (UC)	4.90	3	2	4.4	0.00	1.0e+00	GSDMB STAG3L2 STMN3
High blood pressure (siblings)	4.90	3	1	2.2	0.00	1.0e+00	CLCN6 FNDC4 SH2B3
Impedance of whole body	4.86	6	5	11.1	-0.42	4.1e-01	FNDC4 FTSJ2 NEGR1 RP5-1029K10.2 STAG3L2 ZNF652
Primary Biliary Cirrhosis	4.82	3	2	4.4	0.00	1.0e+00	FNDC4 GSDMB SH2B3
Medication: Atenolol	4.71	2	1	2.2	0.00	1.0e+00	CLCN6 SH2B3
Age when periods started (menarche)	4.66	4	2	4.4	-0.96	4.0e-02	IQCH NEGR1 STAG3L2 ZNF652
Type 2 Diabetes (T2D) (2018)	4.62	3	1	2.2	0.00	1.0e+00	FNDC4 SH2B3 STMN3
Impedance of arm (left)	4.60	6	2	4.4	-0.13	8.0e-01	FNDC4 NEGR1 RP5-1029K10.2 SH2B3 STAG3L2 ZNF652
Medication: Atorvastatin	4.59	1	1	2.2	0.00	1.0e+00	FNDC4
Medication: Ramipril	4.51	4	0	0.0	1.00	1.6e-03	SH2B3 STAG3L2 STMN3 ZNF652
Body Mass Index (BMI) (2010)	4.49	1	1	2.2	0.00	1.0e+00	NEGR1
Alcohol intake versus 10 years previously	4.48	3	1	2.2	0.00	1.0e+00	FNDC4 FTSJ2 NEGR1
Medication: Aspirin	4.48	3	0	0.0	0.00	1.0e+00	FTSJ2 SH2B3 ZNF831
Pulse rate, automated reading	4.44	3	2	4.4	0.00	1.0e+00	FNDC4 NEGR1 STAG3L2
Impedance of arm (right)	4.39	6	3	6.7	-0.16	7.6e-01	FNDC4 NEGR1 RP5-1029K10.2 SH2B3 STAG3L2 ZNF652
Seen doctor (GP) for nerves, anxiety, tension or depression	4.37	3	1	2.2	0.00	1.0e+00	FTSJ2 NEGR1 STMN3
Impedance of leg (right)	4.36	5	4	8.9	-0.53	3.5e-01	FNDC4 NEGR1 RP5-1029K10.2 STAG3L2 ZNF652
Illnesses of siblings	4.35	2	0	0.0	0.00	1.0e+00	CLCN6 SH2B3
Impedance of leg (left)	4.31	6	3	6.7	-0.51	3.0e-01	FNDC4 FTSJ2 NEGR1 RP5-1029K10.2 STAG3L2 ZNF652
Medication: Bendroflumethiazide	4.23	3	0	0.0	0.00	1.0e+00	CLCN6 SH2B3 ZNF831
Overall health rating	4.19	6	1	2.2	0.99	2.8e-04	FTSJ2 IQCH RP5-1029K10.2 STAG3L2 ZNF652 ZNF831
Diabetes diagnosed by doctor	4.15	3	1	2.2	0.00	1.0e+00	FNDC4 SH2B3 STAG3L2
Ulcerative Colitis	4.10	2	2	4.4	0.00	1.0e+00	GSDMB STMN3
Medication: Lisinopril	4.07	2	0	0.0	0.00	1.0e+00	SH2B3 ZNF831
Medication: Aspirin	4.04	1	0	0.0	0.00	1.0e+00	SH2B3
Diabetes (self-reported)	4.01	3	1	2.2	0.00	1.0e+00	FNDC4 STAG3L2 STMN3
Crohns Disease (2012)	4.00	3	1	2.2	0.00	1.0e+00	FNDC4 GSDMB STMN3
BMI	4.00	7	4	8.9	0.65	1.1e-01	CLCN6 FNDC4 FTSJ2 IQCH NEGR1 STAG3L2 ZNF652
Angina	3.95	1	1	2.2	0.00	1.0e+00	ZNF652
Leg fat mass (left)	3.90	6	3	6.7	0.64	1.7e-01	CLCN6 FNDC4 FTSJ2 IQCH NEGR1 STAG3L2
Arm fat-free mass (left)	3.88	3	3	6.7	0.00	1.0e+00	FNDC4 NEGR1 SH2B3
Leg fat mass (right)	3.87	6	3	6.7	0.65	1.6e-01	CLCN6 FNDC4 FTSJ2 IQCH NEGR1 STAG3L2
Waist circumference	3.85	5	3	6.7	0.73	1.6e-01	FNDC4 FTSJ2 IQCH NEGR1 STAG3L2
Arm predicted mass (left)	3.84	3	3	6.7	0.00	1.0e+00	FNDC4 NEGR1 SH2B3
Arm predicted mass (right)	3.82	3	3	6.7	0.00	1.0e+00	FNDC4 NEGR1 SH2B3
Arm fat-free mass (right)	3.79	3	3	6.7	0.00	1.0e+00	FNDC4 NEGR1 SH2B3
High blood pressure (mother)	3.73	2	0	0.0	0.00	1.0e+00	CLCN6 ZNF831
Body fat percentage	3.69	6	3	6.7	0.81	5.1e-02	CLCN6 FTSJ2 IQCH NEGR1 STAG3L2 STMN3
Body mass index (BMI)	3.67	6	3	6.7	0.62	1.9e-01	CLCN6 FNDC4 FTSJ2 IQCH NEGR1 STAG3L2
Whole body fat mass	3.67	6	3	6.7	0.70	1.2e-01	CLCN6 FNDC4 FTSJ2 IQCH NEGR1 STAG3L2
Arm fat mass (right)	3.66	6	3	6.7	0.66	1.5e-01	CLCN6 FNDC4 FTSJ2 IQCH NEGR1 STAG3L2
Hip circumference	3.65	7	5	11.1	0.12	7.9e-01	CLCN6 FNDC4 FTSJ2 IQCH NEGR1 SH2B3 STAG3L2
Arm fat mass (left)	3.64	5	3	6.7	0.74	1.5e-01	FNDC4 FTSJ2 IQCH NEGR1 STAG3L2
Qualifications: College or University degree	3.62	3	1	2.2	0.00	1.0e+00	FTSJ2 NEGR1 STMN3
Angina (self-reported)	3.62	1	0	0.0	0.00	1.0e+00	ZNF652
Whole body water mass	3.62	4	3	6.7	-0.87	1.3e-01	FNDC4 NEGR1 SH2B3 SLC22A5
Trunk predicted mass	3.60	4	2	4.4	-0.90	9.9e-02	FNDC4 NEGR1 SH2B3 SLC22A5
Weight	3.58	7	4	8.9	0.10	8.3e-01	CLCN6 FNDC4 FTSJ2 IQCH NEGR1 SH2B3 STAG3L2
Trunk fat-free mass	3.57	4	2	4.4	-0.90	9.6e-02	FNDC4 NEGR1 SH2B3 SLC22A5
Other serious medical condition/disability diagnosed by doctor	3.56	2	0	0.0	0.00	1.0e+00	NEGR1 STAG3L2
Arm fat percentage (right)	3.55	5	3	6.7	0.79	1.1e-01	CLCN6 FTSJ2 IQCH NEGR1 STAG3L2
Leg fat percentage (left)	3.55	6	3	6.7	0.78	6.5e-02	CLCN6 FTSJ2 IQCH NEGR1 STAG3L2 STMN3
Whole body fat-free mass	3.53	4	3	6.7	-0.87	1.3e-01	FNDC4 NEGR1 SH2B3 SLC22A5
Leg fat percentage (right)	3.50	6	2	4.4	0.79	6.4e-02	CLCN6 FTSJ2 IQCH NEGR1 STAG3L2 STMN3
Basal metabolic rate	3.50	6	3	6.7	-0.32	5.3e-01	FNDC4 IQCH NEGR1 SH2B3 SLC22A5 STAG3L2
Arm fat percentage (left)	3.48	4	4	8.9	0.98	2.4e-02	FTSJ2 IQCH NEGR1 STAG3L2
Number of operations (self-reported)	3.45	3	0	0.0	0.00	1.0e+00	IQCH NEGR1 ZNF652
Chest pain or discomfort	3.42	2	0	0.0	0.00	1.0e+00	GSDMB RP5-1029K10.2
Trunk fat mass	3.41	5	2	4.4	0.76	1.3e-01	CLCN6 FTSJ2 IQCH NEGR1 STAG3L2
Qualifications: nursing, teaching	3.38	2	1	2.2	0.00	1.0e+00	NEGR1 SH2B3
Major Depression (MDD)	3.30	1	1	2.2	0.00	1.0e+00	NEGR1
Trunk fat percentage	3.30	5	2	4.4	0.76	1.4e-01	CLCN6 FTSJ2 IQCH NEGR1 STAG3L2
Leg predicted mass (left)	3.30	6	2	4.4	-0.26	6.3e-01	FNDC4 IQCH NEGR1 SH2B3 SLC22A5 STAG3L2
Leg fat-free mass (left)	3.28	6	2	4.4	-0.26	6.2e-01	FNDC4 IQCH NEGR1 SH2B3 SLC22A5 STAG3L2
Qualifications: None of the above	3.27	3	1	2.2	0.00	1.0e+00	NEGR1 RP5-1029K10.2 STAG3L2
Rheumatoid Arthritis	3.26	2	0	0.0	0.00	1.0e+00	GSDMB SH2B3
Medication: Amlodipine	3.24	2	1	2.2	0.00	1.0e+00	CLCN6 ZNF831
Past tobacco smoking	3.23	3	1	2.2	0.00	1.0e+00	IQCH SH2B3 ZNF652
Average weekly red wine intake	3.23	3	0	0.0	0.00	1.0e+00	FTSJ2 GSDMB NEGR1
Leg predicted mass (right)	3.18	6	2	4.4	-0.29	5.8e-01	FNDC4 IQCH NEGR1 SH2B3 SLC22A5 STAG3L2
Had major operations	3.17	1	0	0.0	0.00	1.0e+00	ZNF652
Leg fat-free mass (right)	3.17	6	2	4.4	-0.29	5.7e-01	FNDC4 IQCH NEGR1 SH2B3 SLC22A5 STAG3L2
Intelligence (Savage-Jansen 2018)	3.16	1	1	2.2	0.00	1.0e+00	NEGR1
Verbal and Numeric Reasoning (VNR)	3.14	1	1	2.2	0.00	1.0e+00	NEGR1
Mouth/teeth dental problems: Dentures	3.11	4	0	0.0	0.01	9.9e-01	FNDC4 GSDMB NEGR1 STAG3L2
Reaction Time	3.10	1	1	2.2	0.00	1.0e+00	SH2B3
Relative age of first facial hair	3.07	4	1	2.2	0.07	9.3e-01	FNDC4 NEGR1 SLC22A5 STAG3L2
Headache pain in last month	3.07	2	0	0.0	0.00	1.0e+00	IQCH ZNF652
Smoking status: Previous	3.07	2	0	0.0	0.00	1.0e+00	IQCH SH2B3
Medication: Metformin	3.00	1	1	2.2	0.00	1.0e+00	FNDC4
Blood Red Count	2.99	7	3	6.7	0.62	1.4e-01	CLCN6 FNDC4 GSDMB SH2B3 STAG3L2 STMN3 ZNF652
Mean time to correctly identify matches	2.98	1	1	2.2	0.00	1.0e+00	SH2B3
Coronary Artery Disease (CAD)	2.97	1	0	0.0	0.00	1.0e+00	SH2B3
Lung FVC	2.94	5	2	4.4	0.05	9.4e-01	FNDC4 GSDMB IQCH SH2B3 STMN3
Current tobacco smoking	2.91	2	1	2.2	0.00	1.0e+00	NEGR1 STMN3
Miserableness	2.91	2	1	2.2	0.00	1.0e+00	FTSJ2 GSDMB
Illnesses of mother	2.90	2	0	0.0	0.00	1.0e+00	ZNF652 ZNF831
Illnesses of father: None of the above (group 1)	2.86	1	0	0.0	0.00	1.0e+00	SH2B3
Multivitamins +/- minerals	2.85	2	0	0.0	0.00	1.0e+00	FTSJ2 NEGR1
Medication for pain relief, constipation, heartburn	2.83	2	0	0.0	0.00	1.0e+00	IL1RL2 ZNF831
Mother's age at death	2.82	1	0	0.0	0.00	1.0e+00	STAG3L2
Qualifications: A levels/AS levels or equivalent	2.78	2	1	2.2	0.00	1.0e+00	FTSJ2 NEGR1
Illnesses of father: Heart disease	2.78	2	0	0.0	0.00	1.0e+00	FNDC4 SH2B3
Smoking status: Current	2.78	1	0	0.0	0.00	1.0e+00	STMN3
HDL Cholesterol	2.76	1	1	2.2	0.00	1.0e+00	GSDMB
Fluid intelligence score	2.73	1	1	2.2	0.00	1.0e+00	NEGR1
Illnesses of father: High blood pressure	2.73	2	0	0.0	0.00	1.0e+00	CLCN6 SH2B3
Depression (Nagel 2018)	2.68	1	0	0.0	0.00	1.0e+00	FTSJ2
Comparative height size at age 10	2.62	5	3	6.7	-0.34	5.8e-01	FNDC4 IQCH SH2B3 SLC22A5 STAG3L2
Bipolar Disorder (2018)	2.61	2	0	0.0	0.00	1.0e+00	FNDC4 GSDMB
Relative age voice broke	2.60	1	0	0.0	0.00	1.0e+00	STAG3L2
Diabetes (father)	2.54	1	0	0.0	0.00	1.0e+00	FNDC4
Pulse rate	2.54	1	1	2.2	0.00	1.0e+00	FNDC4
Lung FEV1/FVC ratio	2.50	5	2	4.4	-0.99	1.9e-03	GSDMB IL1RL2 NEGR1 RP5-1029K10.2 ZNF652
Schizophrenia vs Biploar Disorder	2.47	2	0	0.0	0.00	1.0e+00	FNDC4 GSDMB
Chronic bronchitis/emphysema (father)	2.46	1	0	0.0	0.00	1.0e+00	IQCH
Father's age at death	2.45	1	1	2.2	0.00	1.0e+00	SH2B3
Alcohol usually taken with meals	2.44	2	0	0.0	0.00	1.0e+00	NEGR1 ZNF652
Frequency of unenthusiasm / disinterest in last 2 weeks	2.41	1	0	0.0	0.00	1.0e+00	FTSJ2
Myopia	2.41	2	0	0.0	0.00	1.0e+00	FTSJ2 GSDMB
LDL Cholesterol	2.40	2	0	0.0	0.00	1.0e+00	FNDC4 SH2B3
Pack years adult smoking proportion	2.40	2	0	0.0	0.00	1.0e+00	STAG3L2 STMN3
Ever smoked	2.39	4	0	0.0	1.00	8.7e-05	GSDMB IQCH SH2B3 ZNF652
Depressed Affect (Nagel 2018)	2.37	2	1	2.2	0.00	1.0e+00	FTSJ2 SH2B3
Smoking Status	2.34	3	0	0.0	0.00	1.0e+00	IQCH STMN3 ZNF652
Pack years of smoking	2.33	2	0	0.0	0.00	1.0e+00	STAG3L2 STMN3
Lupus	2.32	2	0	0.0	0.00	1.0e+00	GSDMB SH2B3
Vitamin and mineral supplements	2.27	2	0	0.0	0.00	1.0e+00	FTSJ2 NEGR1
Forced expiratory volume in 1-second (FEV1), predicted percentage	2.25	2	1	2.2	0.00	1.0e+00	GSDMB STMN3
Standing height	2.23	8	6	13.3	-0.56	1.5e-01	FNDC4 FTSJ2 IQCH RP5-1029K10.2 SH2B3 SLC22A5 ZNF652 ZNF831
Osteoarthritis (self-reported)	2.21	1	0	0.0	0.00	1.0e+00	RP11-295M18.6
Height	2.18	9	8	17.8	-0.55	1.3e-01	FNDC4 FTSJ2 IQCH RP11-295M18.6 RP5-1029K10.2 SH2B3 SLC22A5 ZNF652 ZNF831
Mouth/teeth dental problems: Mouth ulcers	2.17	2	0	0.0	0.00	1.0e+00	GSDMB SH2B3
Mean Putamen Volume	2.15	1	0	0.0	0.00	1.0e+00	RP11-295M18.6
Sitting height	2.12	5	3	6.7	-0.64	2.5e-01	FNDC4 RP5-1029K10.2 SLC22A5 ZNF652 ZNF831
Frequency of tiredness / lethargy in last 2 weeks	2.12	2	0	0.0	0.00	1.0e+00	FTSJ2 SH2B3
Neuroticism	2.10	2	1	2.2	0.00	1.0e+00	FTSJ2 IQCH
Neuroticism score	2.07	2	0	0.0	0.00	1.0e+00	FTSJ2 IQCH
Bipolar Disorder or Schizophrenia	2.03	3	0	0.0	0.00	1.0e+00	CLCN6 FTSJ2 GSDMB
Fed-up feelings	2.03	1	1	2.2	0.00	1.0e+00	SH2B3
Age at First Birth	2.02	1	0	0.0	0.00	1.0e+00	ZNF652
Birth weight	1.99	2	1	2.2	0.00	1.0e+00	CLCN6 SH2B3
Commuting to job workplace: Cycle	1.99	1	0	0.0	0.00	1.0e+00	NEGR1
Exposure to tobacco smoke outside home	1.97	1	0	0.0	0.00	1.0e+00	SH2B3
Fractured/broken bones in last 5 years	1.97	1	0	0.0	0.00	1.0e+00	IQCH
Ever depressed for a whole week	1.92	1	0	0.0	0.00	1.0e+00	GSDMB
Diabetes (mother)	1.91	1	0	0.0	0.00	1.0e+00	FNDC4
Pain experienced in last month	1.83	1	0	0.0	0.00	1.0e+00	SH2B3
Supplements: Vitamin C	1.82	1	0	0.0	0.00	1.0e+00	GSDMB
Osteoporosis (self-reported)	1.82	1	0	0.0	0.00	1.0e+00	FNDC4
Medication: Lansoprazole	1.78	1	0	0.0	0.00	1.0e+00	SH2B3
Deep venous thrombosis (DVT) (self-reported)	1.77	1	0	0.0	0.00	1.0e+00	SH2B3
Neuroticism (Nagel 2018)	1.75	1	1	2.2	0.00	1.0e+00	FTSJ2
Blood clot in the leg (DVT)	1.74	1	0	0.0	0.00	1.0e+00	SH2B3
Unable to work because of sickness or disability	1.72	1	0	0.0	0.00	1.0e+00	STAG3L2
Seen a psychiatrist for nerves, anxiety, tension or depression	1.71	1	0	0.0	0.00	1.0e+00	NEGR1
Worry too long after embarrassment	1.69	1	0	0.0	0.00	1.0e+00	IQCH
Forced expiratory volume in 1-second (FEV1), predicted	1.69	1	0	0.0	0.00	1.0e+00	SLC22A5
Loneliness, isolation	1.69	1	0	0.0	0.00	1.0e+00	SH2B3
Age started oral contraceptive pill	1.68	1	0	0.0	0.00	1.0e+00	ZNF652
Commuting to job workplace: Public transport	1.67	1	0	0.0	0.00	1.0e+00	NEGR1
Commuting to job workplace: Car/motor vehicle	1.65	1	0	0.0	0.00	1.0e+00	NEGR1
Guilty feelings	1.63	1	0	0.0	0.00	1.0e+00	FTSJ2
Breast Cancer	1.60	1	0	0.0	0.00	1.0e+00	STAG3L2
Nervous feelings	1.58	1	0	0.0	0.00	1.0e+00	IQCH
Mouth/teeth dental problems	1.57	1	0	0.0	0.00	1.0e+00	STAG3L2
Forced vital capacity (FVC)	1.53	2	2	4.4	0.00	1.0e+00	IQCH STMN3
Mood swings	1.45	2	0	0.0	0.00	1.0e+00	FTSJ2 SH2B3
Average weekly spirits intake	1.44	1	0	0.0	0.00	1.0e+00	FTSJ2
Sensitivity / hurt feelings	1.42	1	0	0.0	0.00	1.0e+00	IQCH
Irritability	1.42	1	0	0.0	0.00	1.0e+00	FTSJ2
Forced vital capacity (FVC), Best measure	1.38	2	1	2.2	0.00	1.0e+00	IQCH STMN3
Stomach or abdominal pain in last month	1.37	1	0	0.0	0.00	1.0e+00	NEGR1
Medication: Gliclazide	1.37	1	0	0.0	0.00	1.0e+00	FNDC4
Worry (Nagel 2018)	1.35	2	0	0.0	0.00	1.0e+00	FTSJ2 IQCH
Hand grip strength (right)	1.35	2	0	0.0	0.00	1.0e+00	FNDC4 SLC22A5
Forced expiratory volume in 1-second (FEV1)	1.34	3	0	0.0	0.00	1.0e+00	IQCH SLC22A5 STMN3
Hair/balding pattern: Pattern 4	1.30	2	0	0.0	0.00	1.0e+00	IQCH SLC22A5
Neuroticism (2016)	1.28	1	0	0.0	0.00	1.0e+00	FTSJ2
Maternal smoking around birth	1.27	1	0	0.0	0.00	1.0e+00	IQCH
Worrier / anxious feelings	1.26	1	0	0.0	0.00	1.0e+00	FTSJ2
Forced expiratory volume in 1-second (FEV1), Best measure	1.24	2	0	0.0	0.00	1.0e+00	SLC22A5 STMN3
Waist Hip Ratio (WHR)	1.19	1	1	2.2	0.00	1.0e+00	IQCH
Hand grip strength (left)	1.18	2	0	0.0	0.00	1.0e+00	FNDC4 SLC22A5
Tense / 'highly strung'	1.18	1	0	0.0	0.00	1.0e+00	FTSJ2
Heel bone mineral density (BMD) T-score, automated (right)	1.17	1	0	0.0	0.00	1.0e+00	IQCH
Heel T-Score	1.12	3	2	4.4	0.00	1.0e+00	IQCH NEGR1 STAG3L2
Back pain experienced in last month	1.11	1	0	0.0	0.00	1.0e+00	SH2B3
Average weekly beer plus cider intake	1.05	1	0	0.0	0.00	1.0e+00	NEGR1
Heel bone mineral density (BMD) T-score, automated (left)	0.94	1	0	0.0	0.00	1.0e+00	IQCH
Suffer from 'nerves'	0.94	1	0	0.0	0.00	1.0e+00	IQCH
Hair Pigment	0.55	3	2	4.4	0.00	1.0e+00	FNDC4 SH2B3 ZNF831
Tanning	0.54	3	1	2.2	0.00	1.0e+00	FNDC4 NEGR1 SH2B3

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Brain Cerebellum	3	0.151	1.9
GTEx	Brain Hippocampus	0	0.000	1.9
GTEx	Pancreas	1	0.061	1.9
GTEx	Prostate	1	0.120	1.9
GTEx	Skin Not Sun Exposed Suprapubic	1	0.041	1.9
GTEx	Whole Blood	1	0.050	1.9
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.187	1.9
GTEx	Adipose Subcutaneous	2	0.057	1.8
GTEx	Adrenal Gland	1	0.069	1.8
GTEx	Artery Aorta	2	0.067	1.8
GTEx	Artery Tibial	2	0.053	1.8
GTEx	Brain Cerebellar Hemisphere	1	0.067	1.8
GTEx	Brain Cortex	1	0.097	1.8
GTEx	Breast Mammary Tissue	0	0.000	1.8
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.8
GTEx	Cells EBV-transformed lymphocytes	0	0.000	1.8
GTEx	Cells Transformed fibroblasts	3	0.071	1.8
GTEx	Colon Transverse	1	0.048	1.8
GTEx	Esophagus Gastroesophageal Junction	2	0.138	1.8
GTEx	Esophagus Mucosa	0	0.000	1.8
GTEx	Esophagus Muscularis	1	0.031	1.8
GTEx	Muscle Skeletal	1	0.035	1.8
GTEx	Ovary	1	0.110	1.8
GTEx	Skin Sun Exposed Lower leg	2	0.055	1.8
GTEx	Small Intestine Terminal Ileum	1	0.217	1.8
GTEx	Spleen	0	0.000	1.8
GTEx	Testis	1	0.032	1.8
GTEx	Thyroid	1	0.025	1.8
GTEx	Vagina	0	0.000	1.8
ROSMAP	Brain Pre-frontal Cortex	4	0.091	1.8
CommonMind	Brain Pre-frontal Cortex	3	0.056	1.8
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	1	0.060	1.8
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	0	0.000	1.8
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	2	0.120	1.8
The Cancer Genome Atlas	Thyroid Carcinoma	2	0.039	1.8
GTEx	Adipose Visceral Omentum	0	0.000	1.7
GTEx	Artery Coronary	0	0.000	1.7
GTEx	Brain Caudate basal ganglia	0	0.000	1.7
GTEx	Brain Frontal Cortex BA9	0	0.000	1.7
GTEx	Brain Nucleus accumbens basal ganglia	1	0.116	1.7
GTEx	Breast Mammary Tissue (Male)	1	0.084	1.7
GTEx	Colon Sigmoid	1	0.068	1.7
GTEx	Heart Atrial Appendage	0	0.000	1.7
GTEx	Heart Left Ventricle	0	0.000	1.7
GTEx	Liver	0	0.000	1.7
GTEx	Lung	2	0.070	1.7
GTEx	Nerve Tibial	2	0.046	1.7
GTEx	Pituitary	0	0.000	1.7
GTEx	Stomach	0	0.000	1.7
GTEx	Uterus	1	0.176	1.7
METSIM	Adipose	0	0.000	1.7
NTR	Blood	0	0.000	1.7
YFS	Blood	1	0.022	1.7
The Cancer Genome Atlas	Breast Invasive Carcinoma	1	0.023	1.7
The Cancer Genome Atlas	Colon Adenocarcinoma	1	0.048	1.7
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.7
The Cancer Genome Atlas	Glioblastoma Multiforme	0	0.000	1.7
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	1	0.024	1.7
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	1	0.049	1.7
The Cancer Genome Atlas	Brain Lower Grade Glioma	3	0.070	1.7
The Cancer Genome Atlas	Lung Adenocarcinoma	2	0.068	1.7
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	0	0.000	1.7
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	1	0.063	1.7
The Cancer Genome Atlas	Prostate Adenocarcinoma	1	0.022	1.7
The Cancer Genome Atlas	Stomach Adenocarcinoma	0	0.000	1.7
The Cancer Genome Atlas	Testicular Germ Cell Tumors	0	0.000	1.7
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.7
GTEx	Brain Putamen basal ganglia	0	0.000	1.6
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	0	0.000	1.6
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	0	0.000	1.6
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	0	0.000	1.6
The Cancer Genome Atlas	Rectum Adenocarcinoma	0	0.000	1.6
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	1.6
GTEx	Brain Hypothalamus	0	0.000	1.5